• Male or female and ≥ 18 years of age

• Histologically and/or cytologically confirmed primary diagnosis of R/M HNSCC

• Participants with oropharyngeal cancer will be required to have proof of p16 negative status submitted on the basis of a pathology report

• At least 1 measurable lesion by contrast CT or MRI scan according to RECIST v.1.1. Such lesions must not have been previously irradiated; if the measurable lesion(s) has been irradiated, clear progression must be documented

• Participants must have failed prior therapy with an anti-PD-1/PD-L1 ICI and with platinum-based chemotherapy administered in combination or sequentially, in either the locally advanced or R/M setting. Failure of prior treatment may be due to progression of disease or intolerance to treatment

• Patient's tumor must be considered inoperable and incurable

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with a life expectancy of at least 12 weeks

• For women of childbearing potential (WOCBP), documentation of negative serum pregnancy test within 30 days of randomization

• For WOCBP and male participants whose sexual partners are of childbearing potential, agreement to use an effective method of contraception during the study and for at least 5 months after the last dose of study treatment. Birth control methods which may be considered highly effective include methods that achieve a failure rate of less than 1% per year when used consistently and correctly.

• Ability to give written informed consent and comply with protocol requirements

• Patients with feeding tubes are eligible for the study.

• Archived tissue sample must be submitted to the Sponsor-designated laboratory within 60 days of randomization for c-Met analysis (if a tissue sample is not available, a fresh biopsy may be required prior to enrollment)